Tissue oxygenation monitoring in heart failure

Patent metadata

Field	Value
Publication number	US-10179242-B2
Application number	US-79781510-A
Country	US
Kind code	B2
Filing date	Jun 10, 2010
Priority date	Jun 10, 2009
Publication date	Jan 15, 2019
Grant date	Jan 15, 2019

Abstract

A medical device for monitoring delivery of a therapy that includes a therapy delivery module to deliver a therapy, a controller to set a therapy delivery control parameter, an optical sensor to produce a signal corresponding to tissue light attenuation, and a processor configured to compute a tissue oxygenation measurement from the optical sensor signal, wherein the controller, the optical sensor, and the processor operate cooperatively to determine a setting of the therapy delivery control parameter corresponding to a maximum tissue oxygenation.

First claim

The invention claimed is:

1. A medical device comprising:
a therapy delivery module configured to deliver a therapy based on a therapy delivery control parameter;
an optical sensor for sensing a signal of light attenuated by a localized volume of a blood-perfused body tissue;
a processor configured to:
compute a tissue oxygenation measurement of an availability of oxygen at the localized tissue volume from the optical sensor signal during the therapy being delivered based on the therapy delivery control parameter,
detect a decrease in tissue oxygenation by comparing the tissue oxygenation measurement to a threshold; and
determine an adjusted therapy delivery control parameter in response to the decrease in tissue oxygenation tissue oxygenation.

2. The device of claim 1 , wherein the optical sensor comprises a light emitting portion for emitting at least four spaced apart wavelengths and a light detecting portion for producing a signal corresponding to the tissue light attenuation at the at least four spaced apart wavelengths.

3. The device of claim 2 , wherein the processor is configured to compute a second derivative of the tissue light attenuation with respect to wavelength and computes an absolute tissue oxygen saturation using the second derivative.

4. The device of claim 3 , further comprising the processor being configured to compute a total hemoglobin volume fraction using the absolute tissue oxygen saturation.

5. The device of claim 4 , wherein the processor is configured to determine the adjusted therapy delivery control parameter corresponding to one of a maximum tissue oxygen saturation and a maximum total hemoglobin volume fraction.

6. The device of claim 4 , wherein the processor is configured to compute a tissue oxygenation index using the tissue oxygen saturation and the total hemoglobin volume fraction and to determine the adjusted therapy delivery control parameter corresponding to a maximum tissue oxygenation index.

7. The device of claim 1 , wherein the optical sensor is an external sensor emitting light transcutaneously.

8. The device of claim 1 , wherein the optical sensor is an implantable sensor.

9. The device of claim 8 , further comprising a sealed housing, wherein the optical sensor is configured within the sealed housing.

10. The device of claim 8 , further comprising an electrical lead electrically coupled to the medical device, the lead comprising an elongated lead body, wherein the optical sensor is positioned along the elongated lead body.

11. The device of claim 8 , further comprising a medical device telemetry module, wherein the optical sensor comprises:
a sealed housing; and
a sensor telemetry module configured for bidirectional communication with the medical device telemetry module.

12. The device of claim 1 , wherein the optical sensor comprises a light detecting portion and a light emitting portion, one of the light detecting portion and the light emitting portion being an implantable portion and the other of the light detecting portion and the light emitting portion being an external portion positioned in facing opposition with the implantable portion.

13. The device of claim 12 , wherein the control parameter comprises one of an electrode location, a timing parameter and an electrode selection parameter.

14. The device of claim 1 , further comprising:
a plurality of electrodes for stimulating at least one heart chamber;
a pulse generator configured to deliver pacing pulses to the at least one heart chamber via the plurality of electrodes, wherein the control parameter corresponds to a parameter for controlling cardiac resynchronization therapy.

15. The device of claim 1 , wherein the therapy delivery module comprises:
a catheter; and
a fluid delivery module.

16. The device of claim 1 , wherein the therapy delivery module comprises:
a plurality of electrodes; and
a pulse generator configured to deliver stimulation pulses to a nerve via the plurality of electrodes.

17. The device of claim 1 , wherein the medical device comprises a cardiac assist device for delivering the therapy.

18. The device of claim 1 , further comprising a memory configured to store tissue oxygenation measurements determined by the processor,
wherein the processor is configured to detect the decrease in tissue oxygenation by comparing the tissue oxygenation measurement to a previously determined tissue oxygenation measurement stored in the memory as one of an initial baseline tissue oxygenation measurement or a running average tissue oxygenation measurement.

19. The device of claim 1 , wherein the processor is configured to determine the adjusted therapy delivery control parameter by determining a duty cycle of the therapy that maintains the tissue oxygenation at a stable level.

20. The device of claim 1 , wherein the therapy delivery module is configured to deliver cardiac resynchronization therapy and the processor is configured to determine the adjusted therapy delivery control parameter by determining a duty cycle of the cardiac resynchronization therapy.

21. The device of claim 1 , wherein the processor is configured to determine the adjusted therapy delivery control parameter by determining a duty cycle of a blood pump.

22. The device of claim 1 , wherein the processor is configured to:
detect an increase in the tissue oxygenation; and
determine the adjusted therapy delivery control parameter to reduce therapy delivery in response to detecting the increase in the tissue oxygenation.

23. The device of claim 1 , wherein the processor is configured to determine the adjusted therapy delivery control parameter to maximize the tissue oxygenation measurement when a heart rate is within a predefined heart rate range.

24. The device of claim 1 , further comprising a sensor configured to sense a cardiac electrical signal,
wherein the processor is configured to determine a resting heart rate of a patient from the sensed cardiac electrical signal, and
wherein the processor is further configured to determine the adjusted therapy delivery control parameter to lower the resting heart rate and maintain the tissue oxygenation within a predetermined range.

25. A method for monitoring delivery of a therapy in a medical device, comprising;
delivering a therapy based on a therapy delivery control parameter;
sensing an optical sensor signal of light attenuated by a localized volume of blood-perfused body tissue;
computing a tissue oxygenation measurement of an availability of oxygen at the localized tissue volume from the optical sensor signal during the therapy being delivered based on the therapy delivery control parameter;
detecting a decrease in tissue oxygenation by comparing the tissue oxygenation measurement to a threshold; and
determining an adjusted therapy delivery control parameter in response to the decrease in tissue oxygenation tissue oxygenation.

26. The method of claim 25 , wherein delivering the therapy comprises delivering pacing pulses to at least one heart chamber.

27. The method of claim 26 , wherein the control parameter comprises one of an electrode location, a timing parameter and an electrode selection parameter.

28. The method of claim 25 , wherein delivering the therapy comprises delivering a heart failure medication.

29. The method of claim 25 , wherein delivering the therapy compr

Assignees

• Cinbis Can
• Carney James K
• Kuhn Jonathan L
• Anderson David A
• Medtronic Inc

Inventors

• Cinbis Can
• Carney James K
• Kuhn Jonathan L
• Anderson David A

Classifications

• A61N1/36557 Primary

  controlled by chemical substances in blood · CPC title